An open-label, phase 1b, dose-escalation study (CA180-373) of dasalinib plus itivollimab, an investigational anti-programmed cell death 1 (PD-1) antibody, in patients (pts) with previously treated chronic myeloid leukemia (CML) Meeting Abstract
| Authors: | Porkka, K.; Mauro, M. J.; Lipton, J. H.; Mahon, F. X.; Strauss, L. C.; Geese, W. J.; Kroog, G. S.; Mustjokl, S. |
| Abstract Title: | An open-label, phase 1b, dose-escalation study (CA180-373) of dasalinib plus itivollimab, an investigational anti-programmed cell death 1 (PD-1) antibody, in patients (pts) with previously treated chronic myeloid leukemia (CML) |
| Meeting Title: | 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 32 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2014 May 30-Jun 3 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2014-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358613202183 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2014.32.15_suppl.TPS7119 |
| Notes: | Meeting Abstract: TPS7119 -- Source: Wos |
